CUE – Cue Biopharma Inc
Cue Biopharma, Inc.CUE
$0.762Name : Cue Biopharma, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $57,416,628.00
EPSttm : -0.72
Cue Biopharma, Inc.
$0.762
2.18%$0.017Float Short %
1.39
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
EPS Last/This Y
0.13
EPS This/Next Y
-0.06
Price
0.76
Target Price
2
Analyst Recom
1
Performance Q
-40.47
Relative Volume
0.53
Beta
1.5
Ticker: CUE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | CUE | 0.9403 | 0.11 | 0.00 | 766 |
| 2025-03-21 | CUE | 0.9846 | 0.11 | 0.00 | 776 |
| 2025-03-24 | CUE | 1.01 | 0.11 | 26.00 | 744 |
| 2025-03-25 | CUE | 0.982 | 0.13 | 0.00 | 756 |
| 2025-03-26 | CUE | 0.9801 | 0.13 | 0.00 | 756 |
| 2025-03-27 | CUE | 1 | 0.13 | 0.00 | 726 |
| 2025-03-28 | CUE | 0.9545 | 0.13 | 0.00 | 730 |
| 2025-03-31 | CUE | 0.8954 | 0.13 | 0.00 | 733 |
| 2025-04-01 | CUE | 0.7511 | 0.13 | 0.00 | 733 |
| 2025-04-02 | CUE | 0.7919 | 0.13 | 0.00 | 733 |
| 2025-04-03 | CUE | 0.7762 | 0.13 | 0.00 | 733 |
| 2025-04-04 | CUE | 0.6882 | 0.13 | 999.99 | 734 |
| 2025-04-07 | CUE | 0.6258 | 0.16 | 0.00 | 752 |
| 2025-04-08 | CUE | 0.6179 | 0.17 | 0.00 | 727 |
| 2025-04-09 | CUE | 0.6872 | 0.17 | 0.00 | 728 |
| 2025-04-10 | CUE | 0.7 | 0.17 | 0.00 | 728 |
| 2025-04-11 | CUE | 0.755 | 0.17 | 0.00 | 728 |
| 2025-04-14 | CUE | 0.818 | 0.17 | 0.00 | 728 |
| 2025-04-15 | CUE | 0.798 | 0.17 | 0.00 | 728 |
| 2025-04-16 | CUE | 0.7821 | 0.17 | 0.00 | 728 |
| 2025-04-17 | CUE | 0.7601 | 0.17 | 0.00 | 734 |
| 2025-04-18 | CUE | 0.762 | 0.17 | 0.00 | 734 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | CUE | 0.96 | 50.0 | - | -0.76 |
| 2025-03-21 | CUE | 0.98 | 50.0 | - | -0.76 |
| 2025-03-24 | CUE | 1.03 | 50.0 | - | -0.76 |
| 2025-03-25 | CUE | 1.00 | 50.0 | - | -0.76 |
| 2025-03-26 | CUE | 0.99 | 50.0 | - | -0.76 |
| 2025-03-27 | CUE | 1.01 | 50.0 | - | -0.76 |
| 2025-03-28 | CUE | 0.92 | 50.0 | - | -0.76 |
| 2025-03-31 | CUE | 0.91 | 50.0 | - | -0.76 |
| 2025-04-01 | CUE | 0.75 | 50.0 | - | -0.76 |
| 2025-04-02 | CUE | 0.79 | 50.0 | - | -0.76 |
| 2025-04-03 | CUE | 0.75 | 50.0 | - | -0.76 |
| 2025-04-04 | CUE | 0.68 | 50.0 | - | -0.46 |
| 2025-04-07 | CUE | 0.64 | 50.0 | - | -0.46 |
| 2025-04-08 | CUE | 0.62 | 50.0 | - | -0.46 |
| 2025-04-09 | CUE | 0.70 | 50.0 | - | -0.46 |
| 2025-04-10 | CUE | 0.71 | 50.0 | - | -0.46 |
| 2025-04-11 | CUE | 0.78 | 50.0 | - | -0.46 |
| 2025-04-14 | CUE | 0.79 | 50.0 | - | -0.46 |
| 2025-04-15 | CUE | 0.80 | 50.0 | - | -0.46 |
| 2025-04-16 | CUE | 0.77 | 50.0 | - | -0.46 |
| 2025-04-17 | CUE | 0.76 | 50.0 | - | -0.46 |
| 2025-04-18 | CUE | 0.76 | 50.0 | - | -0.59 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | CUE | 6.74 | -14.33 | 1.52 |
| 2025-03-21 | CUE | 6.74 | -14.33 | 1.52 |
| 2025-03-24 | CUE | 6.74 | -14.33 | 1.52 |
| 2025-03-25 | CUE | 6.74 | -14.33 | 1.52 |
| 2025-03-26 | CUE | 6.74 | -14.33 | 1.37 |
| 2025-03-27 | CUE | 6.74 | -14.33 | 1.37 |
| 2025-03-28 | CUE | 6.74 | -14.33 | 1.37 |
| 2025-03-31 | CUE | 6.74 | -14.33 | 1.37 |
| 2025-04-01 | CUE | 6.74 | -14.33 | 1.37 |
| 2025-04-02 | CUE | 6.74 | -14.33 | 1.37 |
| 2025-04-03 | CUE | 6.92 | -14.33 | 1.40 |
| 2025-04-04 | CUE | 6.92 | -14.33 | 1.40 |
| 2025-04-07 | CUE | 6.92 | -14.64 | 1.40 |
| 2025-04-08 | CUE | 6.92 | -14.64 | 1.40 |
| 2025-04-09 | CUE | 6.92 | -14.64 | 1.40 |
| 2025-04-10 | CUE | 6.92 | -14.64 | 1.39 |
| 2025-04-11 | CUE | 6.92 | -14.64 | 1.39 |
| 2025-04-14 | CUE | 6.92 | -14.34 | 1.39 |
| 2025-04-15 | CUE | 6.92 | -14.34 | 1.39 |
| 2025-04-16 | CUE | 6.92 | -14.34 | 1.39 |
| 2025-04-17 | CUE | 6.92 | -14.34 | 1.39 |
| 2025-04-18 | CUE | 6.92 | -14.34 | 1.39 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
-0.14
Insider Transactions
6.92
Institutional Transactions
-14.34
Beta
1.5
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
20
Growth Score
34
Sentiment Score
74
Actual DrawDown %
97.6
Max Drawdown 5-Year %
-98.5
Target Price
2
P/E
Forward P/E
PEG
P/S
6.18
P/B
2.69
P/Free Cash Flow
EPS
-0.75
Average EPS Est. Cur. Y
-0.59
EPS Next Y. (Est.)
-0.66
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-437.97
Relative Volume
0.53
Return on Equity vs Sector %
-252.4
Return on Equity vs Industry %
-239
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
Cue Biopharma, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 41
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
stock quote shares CUE – Cue Biopharma Inc Stock Price stock today
news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CUE – Cue Biopharma Inc yahoo finance google finance
stock history CUE – Cue Biopharma Inc invest stock market
stock prices CUE premarket after hours
ticker CUE fair value insiders trading